Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer

15–40% of non-small cell lung cancer (NSCLC) patients harbor epidermal growth factor receptor (EGFR)-sensitizing mutations. Tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in this population, yet all patients will ultimately progress. Liquid biopsy can reliably identify somati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Hsiang-Ling, Jiang, Yuqiu, Chiang, Chi-Lu, Karwowska, Sylwia, Yerram, Ranga, Sharma, Keerti, Scudder, Sidney, Chiu, Chao-Hua, Tsai, Chun-Ming, Palma, John F., Sharma, Abha, Chou, Teh-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049536/
https://www.ncbi.nlm.nih.gov/pubmed/35482671
http://dx.doi.org/10.1371/journal.pone.0267362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049536/
https://www.ncbi.nlm.nih.gov/pubmed/35482671
http://dx.doi.org/10.1371/journal.pone.0267362

Ejemplares similares